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S. Chochua1, M. Sheth4, N. Rayamajhi1, S. D. Bentley2,3, L. Kim1, C. G. Whitney1, L. McGee1 and B. Beall1, on behalf of the Active
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Emerging and Zoonotic Infectious Diseases, Atlanta, GA, USAAbstractThe effect of second-generation pneumococcal conjugate vaccines on invasive pneumococcal disease (IPD) strain distributions have not yet
been well described. We analysed IPD isolates recovered from children aged <5 years through Active Bacterial Core surveillance before
(2008–2009; n = 828) and after (2011–2013; n = 600) 13-valent pneumococcal conjugate vaccine (PCV13) implementation. We
employed conventional testing, PCR/electrospray ionization mass spectrometry and whole genome sequence (WGS) analysis to identify
serotypes, resistance features, genotypes, and pilus types. PCV13, licensed in February 2010, effectively targeted all major 19A and 7F
genotypes, and decreased antimicrobial resistance, primarily owing to removal of the 19A/ST320 complex. The strain complex
contributing most to the remaining β-lactam resistance during 2011–2013 was 35B/ST558. Signiﬁcant emergence of non-vaccine clonal
complexes was not evident. Because of the removal of vaccine serotype strains, positivity for one or both pilus types (PI-1 and PI-2)
decreased in the post-PCV13 years 2011–2013 relative to 2008–2009 (decreases of 32–55% for PI-1, and >95% for PI-2 and combined
PI-1 + PI-2). β-Lactam susceptibility phenotypes correlated consistently with transpeptidase region sequence combinations of the three
major penicillin-binding proteins (PBPs) determined through WGS analysis. Other major resistance features were predictable by DNA
signatures from WGS analysis. Multilocus sequence data combined with PBP combinations identiﬁed progeny, serotype donors and
recipient strains in serotype switch events. PCV13 decreased the frequency of all PCV13 serotype clones and concurrently decreased the
frequency of strain subsets with resistance and/or adherence features conducive to successful carriage. Our results serve as a reference
describing key features of current paediatric IPD strains in the USA after PCV13 implementation.
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p://dx.doi.org/10.1016/j.cmi.2015.08.027IntroductionStreptococcus pneumoniae can quickly adapt to selective pres-
sures through horizontal transfer and intrachromosomal mu-
tation events. Even so, the conjugate vaccine strategy of
targeting currently predominant invasive serotypes has been
highly successful [1,2] and durable [3] in decreasing thelinical Microbiology and Infectious Diseases
.0/)
CMI Metcalf et al. Population-based invasive pneumococcal strain distribution in the USA 60.e10frequency of invasive pneumococcal disease (IPD) and pneu-
mococcal antimicrobial resistance. However, individual variants
that originated through serotype-switching events substantially
contributed to disease burdens in the USA in the post-seven-
valent pneumococcal conjugate vaccine (PCV7) era [4–8].
Although the monitoring of pneumococcal serotypes and
antimicrobial susceptibilities provides the major information for
devising prevention strategies, approaches that deduce the
causal chromosomal changes that lead to the emergence of
individual invasive strains allow for a better biological and
epidemiological understanding of pneumococcal strains. Here,
we have provided a strain reference that supplies distributions
and genetic features of each invasive serotype that we detected
in a US surveillance system during a key 5-year period of IPD
surveillance.Materials and methodsPatients
Active Bacterial Core surveillance (ABCs) is an active,
population-based and laboratory-based surveillance system that
is part of the CDC Emerging Infections Program. Cases of IPD
were deﬁned by the isolation of pneumococci from a normally
sterile site in residents of the surveillance areas in ten different
states [1–3] (see ABCs surveillance reports for population sizes
and IPD incidence at http://www.cdc.gov/abcs/reports-ﬁndings/
surv-reports.html). Throughout the entire 2005–2013 period,
the number of individuals aged <5 years in the ABCs catchment
area remained approximately 2.1 million.
Isolates
For the years of the primary focus (2008–2009 and 2011–2013),
isolates corresponding to 84.7–90.4% of reported cases were
available to the CDC Streptococcus Laboratory for characteriza-
tion (average, 87.9%). For each of these 5 years, all of these
isolates were characterized with respect to serotypes, multilocus
sequence type (MLST)-based clonal complexes (CCs), resistance
features, and pilin subunit presence or absence.
Isolates were characterized by use of a combination of
conventional testing, PCR/electrospray ionization mass spec-
trometry (ESI-MS), and short-read whole genome sequence
(WGS) analysis. In total, 1428 isolates, corresponding to 87.9%
of the 1625 documented IPD cases in children aged <5 years,
were available for characterization (828/948 for 2008–2009,
and 600/677 for 2011–2013) (Supplementary Fig. S1).
Capsular serotyping
All isolates from 2005 through 2013 were serotyped with latex
agglutination and the Quellung reaction employing CDC antisera.Clinical Microbiology and Infection published by Elsevier Ltd on behalf of E
This is an oWGS analysis
Of the 801 combined year 2009, 2012 and 2013 IPD isolates
described in this study, serotypes, antimicrobial susceptibilities,
MLSTs and pilus types for 699 (87.3%) were determined by the
use of our pneumococcal typing pipeline with Illumina WGS
fastq ﬁles provided by the Sanger group (n = 516 from year
2009 and 2012 IPD isolates) and the CDC Biotechnology Core
Facility (n = 183 from year 2013 IPD isolates). The WGS-
derived data from these 699 isolates recovered during 2009,
2012 and 2013 were used to supplement the already accumu-
lated conventional serotyping, antimicrobial susceptibility
testing, MLST, pilus locus PCR and PCR/ESI-MS data (described
below). WGS-based identiﬁcation of serotypes, pilus loci and
non-β-lactam antimicrobial resistance features employed query
DNA sequences described in Table S1 (serotypes and pili) and
Table S2 (non-β-lactam antimicrobial resistance). Trans-
peptidase domain amino acid sequences of 277–359 residues
from penicillin-binding proteins (PBPs) 1a, 2b, and 2x were
extracted from approximately 1600 ABCs strains characterized
over the years 1998–2013. From this, databases of 69, 77 and
127 unique transpeptidase domain amino acid sequences were
compiled for PBP1a, PBP2b, and PBP2x, respectively
(Tables S3–S5). Each unique sequence was assigned an identi-
ﬁer (sequences 1a-0 to 1a-68 for PBP1a, sequences 2b-0 to 2b-
78 for PBP2b, and sequences 2x-0 to 126 for PBP2x). The
three-number combination from each isolate was correlated
with MICs for each of the six different β-lactam antibiotics. For
example, the basally β-lactam-sensitive TIGR4 strain (genbank
accession AE005672) contains a composite amino acid
sequence pattern of 1a-0, 2b-0, and 2x-0 (abbreviated as 0:0:0).
The corresponding DNA sequences (e.g. 1a-0, 2b-0, and 2x-0)
are italicized. Full-length PBP genes are referred to with stan-
dard nomenclature (pbp1a, pbp2b, and pbp2x).
Detection of non-core genome-conferred resistance loci
was performed according to homology with known de-
terminants. Core genome-encoded resistance determinants
(ﬂuoroquinolones, co-trimoxazole, ribosomal protein
mutation-conferred macrolide/lincosamide/streptogramin
resistance, and rifampin) were screened by identifying speciﬁc
amino acid substitutions with previously described targets
(Table S2). Table S2 describes the sequence coordinates used
for resistance queries. The bioinformatics methods used are
described in Doc. S1.
Serotype veriﬁcation, CC determination and pilus
determinant detection for year 2008 and 2011 isolates
Quellung-determined serotypes were veriﬁed from IPD isolates
(n = 622) from 2008 and 2011 by use of the previously
described PCR/ESI-MS) [9]. CCs were assigned on the basis of
known clone and serotype associations with partial to completeuropean Society of Clinical Microbiology and Infectious Diseases, CMI, 22, 60.e9–60.e29
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bial resistance proﬁles as previously described [8,10]; these
CCs were then veriﬁed with PCR/ESI-MS. Year 2009 isolates,
most of which were also subjected to WGS analysis as
described above, were processed in the same manner, except
without PCR/ESI-MS. Pilus determinant PCR-based detection
was performed with previously described primers [11].
Twenty-ﬁve of the year 2008 isolates were also retrospectively
subjected to the WGS typing pipeline. Serotypes, pilus de-
terminants and MLSTs obtained with WGS were in complete
concordance with the results obtained with the other methods.
Assignment of CC reference MLSTs
Multilocus sequence typing relied upon the database at http://
pubmlst.org/spneumoniae/. Forty-seven new sequence types
(STs) and 21 new MLST alleles from this study were deposited
in this database. CCs were deﬁned as sharing four or more
alleles with a given reference ST. CC reference STs were
chosen according to abundance within a given serotype and/or
their presence within multiple serotypes of the study, and
differed by at least three alleles from other CC reference STs.
Antimicrobial susceptibility
MICs were determined with the microbroth dilution method as
previously described [8]. The antimicrobials tested included
penicillin, amoxycillin, meropenem, cefotaxime, ceftriaxone,
cefuroxime, erythromycin, clindamycin, co-trimoxazole, tetra-
cycline, chloramphenicol, rifampin, levoﬂoxacin, synercid, line-
zolid, telithromycin, and vancomycin. MICs were interpreted
according to 2013 CLSI guidelines [12], with exceptions for the
different β-lactam antibiotics and chloramphenicol. Penicillin
susceptibility, intermediate resistance, resistance and high-level
resistance were deﬁned as (in mg/L) 0.06, 0.12–1.0, 2.0, and
4, respectively. The highest MIC observed for cefotaxime
and/or ceftriaxone was used as a single MIC value for third-
generation cephalosporins (these two antibiotics usually
showed the same MIC, and never varied by more than a single
dilution), with susceptibility, intermediate resistance, resistance
and high-level resistance deﬁned as 0.5, 1.0, 2.0, and 4,
respectively. For amoxycillin, susceptibility, intermediate resis-
tance, resistance and high-level resistance were deﬁned as
0.12, 0.25–1, 2.0, and 4, respectively. For meropenem,
susceptibility, intermediate resistance, resistance and high-level
resistance were deﬁned at 0.25, 0.5, 1.0, and 2.0, respec-
tively. Only chloramphenicol MICs of >8 mg/L were considered
to indicate resistance, differing from the CLSI value of 8 mg/L.
Intermediate and full co-trimoxazole (trimethoprim–
suphamethoxazole) resistance was deﬁned as MICs (for
trimethoprim–sulphamethoxazole) of 1/19–2/38 mg/L and 4/
76 mg/L, respectively.Clinical Microbiology and Infection published by Elsevier Ltd on behalf of European Society of C
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Accession information and sequencing methodology details for
the 727 fastq ﬁles utilized in this work are provided in Table S6.ResultsIPD due to PCV13-targeted serotypes
A total of 3024 isolates were collected through ABCs during
2005–2013 from 3443 cases of IPD in children aged <5 years.
The percentage of IPD cases with corresponding isolates
ranged from 84% to 91% (Fig. 1). During 2005–2009, overall
rates of IPD in children aged <5 years of age remained at 21–23
cases per 100 000 individuals [2], as reﬂected by 384–443 IPD
isolates for each of these years within the surveillance popu-
lation (Fig. 1). The yearly number of 13-valent pneumococcal
conjugate vaccine (PCV13) serotype isolates ranged from 223
to 290, accounting for 58–65% of the total IPD isolates. As
recently reported [2], the major causes of IPD in children aged
<5 years immediately prior to PCV13 implementation (early
2010) were PCV13 serotypes 19A and 7F. During 2005–2009,
the numbers of serotype 19A and 7F isolates for each year
were 136–190 and 27–71, respectively, with the largest
numbers of isolates for both serotypes being recovered during
2009. The incidence of these serotypes dropped dramatically
during 2011–2013, with only 14 serotype 19A isolates and two
serotype 7F isolates being recovered during 2013. PCV7 se-
rotypes and serotype 6A cumulatively accounted for only 76
isolates during 2005–2009 (3.7%) and for 15 isolates during
2011–2013 (2.5%). Serotype 19F was the most common PCV7-
targeted serotype encountered, with 33 isolates (43.4%) being
recovered during 2005–2009 and nine isolates (60%) being
recovered during 2011–2013. Throughout the 9-year period,
there was a general trend for a decrease in the number of
PCV7-targeted serotypes, from a high of 28 isolates recovered
during 2005 to a low of four isolates recovered during 2013.
There were no isolates recovered of the four PCV7-targeted
serotypes 6A, 6B, 9V and 23F during 2011–2013, as
compared with 23 recovered during 2005–2009.
Whereas there were a small number of IPD cases due to
PCV13 serotypes 1 and 5 during 2005–2009 (29 serotype 1
and ﬁve serotype 5 isolates recovered), there were no cases
detected during 2010–2012, and there was only one serotype 1
isolate recovered during 2013. The minor paediatric IPD
serotype 6C is also predicted to be targeted by PCV13 through
cross-protection from the 6A antigen [13], which adds a small
increment to the total of potential PCV13-preventable cases
(5–12 cases during each of the years 2005–2012; total of 64
isolates). There was no reported serotype 6C paediatric IPD
during 2013; however, paediatric serotype 6C IPD in priorlinical Microbiology and Infectious Diseases, CMI, 22, 60.e9–60.e29
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FIG. 1. Invasive pneumococcal disease (IPD) isolate serotype distributions in children aged <5 years during 2005–2013 as identiﬁed through Active
Bacterial Core surveillance. Thirteen-valent pneumococcal conjugate vaccine (PCV13) serotypes and 6C are bracketed. The arrow indicates PCV13
implementation in February, 2010. The percentages shown above each year indicate the ratios of IPD isolates to documented IPD cases (see http://
www.cdc.gov/abcs/reports-ﬁndings/surv-reports.html). NT, non-typeable; PCV7, seven-valent pneumococcal conjugate vaccine.
CMI Metcalf et al. Population-based invasive pneumococcal strain distribution in the USA 60.e12years was too rare for the signiﬁcance of this ﬁnding to be
calculated.
IPD due to non-PCV13 serotypes
The four most frequent causes of IPD during 2011–2013 were
serotypes 33F, 22F, 15B/15C, and 35B; there were cumulatively
244 isolates recovered of these four serotypes during these
three years (72–88 isolates per year). Serotypes 38, 12F, 23B,
10A, 15A and 23A combined accounted for 120 isolates during
these three years (36–42 each year). Each of these non-vaccine
serotypes showed relatively little ﬂuctuation in IPD incidence
throughout the entire period (2005–2013), and there were no
clear indications of so-called serotype replacement disease.
Although the number of 33F IPD isolates nearly doubled in 2013
(n = 25) relative to 2012 (n = 14), the numbers of serotype 33F
IPD isolates recovered were nearly identical during each of the
years 2005, 2008, 2009, 2011, and 2013 (Fig. 1). The remaining,
less frequently encountered, non-PCV13 serotypes that were
encountered during the 2005–2013 period, listed according to
frequency (cumulative isolates), were 16F (38), 11A (37), 21
(29), 8 (19), 9N (19), 17F (18), 35F (17), 34 (14), 7C (12), 20 (8),Clinical Microbiology and Infection published by Elsevier Ltd on behalf of E
This is an o31 (8), 13 (3), 11B (1), 12B (1), 18B (1), 24F (1), 27 (1), and 28A
(1). These serotypes also showed no clear indications of
becoming increasingly common after PCV13 introduction, and
cumulatively accounted for only 18–31 isolates each year during
2005–2013 (18–28 during 2011–2013). There were 24 total
non-typeable (NT) IPD isolates recovered during 2005–2013.
Features of the nine NT isolates recovered during 2008–2009
and 2011–2013 are described below.
Serotype and genotype diversity of invasive
pneumococci recovered during 2008–2013
A total of 1428 IPD isolates were characterized from the years
2008–2009 and 2011–2013. Fig. 2 is provided to give a
comprehensive representation of the CC diversity within each
serotype during these 5 years. This work included WGS-based
characterization of 699 isolates recovered during 2009, 2012,
and 2013 (Table 1), representing 35 of the 39 serotypes that,
together with nine NT isolates, accounted for all IPD cases
during the 5 years of the study (serotype 6A, 6B, 14 and 20
isolates were not recovered during 2009, 2012, and 2013). The
WGS data included WGS-derived capsular serotypes, MLSTs,uropean Society of Clinical Microbiology and Infectious Diseases, CMI, 22, 60.e9–60.e29
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FIG. 2. Comprehensive listing of clonal complex (CC) associations with the serotypes encountered in invasive pneumococcal disease (IPD) isolates
during 2008–2009 and 2011–2013. Asterisks indicate CCs that were encountered in single isolates. Thirteen-valent pneumococcal conjugate vaccine
(PCV13) serotypes and 6C are bracketed. Certain variants are presented as percentages; for example 7F (191) constitutes 96% of serotype 7F, and 7F
(220) constitutes 4%. NT, non-typeable.
60.e13 Clinical Microbiology and Infection, Volume 22 Number 1, January 2016 CMItranspeptidase protein sequence type patterns, pilus determi-
nant detection, and sequence-based antimicrobial resistance
markers (correlated with conventional MIC-based results).
Genetic composition of individual non-vaccine type
(NVT) serotypes
Below, we provide selected information regarding speciﬁc NVT
serotypes of interest from among the 27 total NVTs encoun-
tered. We have restricted this text to predominant serotypes
and individual variants that potentially reﬂect past serotype
switch events or express unusual resistance properties within
given serotypes.
Serotypes 22F and 33F
Serotypes 22F and 33F were each composed primarily of single
MLST-based complexes that appear to have been largely un-
changed throughout 2008–2013 and in comparison with the
year immediately before PCV7 introduction (1999) [14]. Both
serotypes uniformly lacked pilus determinants PI-1 and PI-2
(Table 1). As also shown in Table 1, approximately 25% of
serotype 22F isolates recovered during 2009, 2012 and 2013
expressed mef-associated erythromycin resistance. Most sero-
type 33F isolates were resistant to erythromycin (mef-positive)Clinical Microbiology and Infection published by Elsevier Ltd on behalf of European Society of C
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4and were primarily intermediately resistant to co-trimoxazole.
Intermediate co-trimoxazole resistance in these and most other
isolates of this phenotype, was associated with one or two
codon insertions between bases 168 and 201 of the folP
structural gene. A small number of serotype 33F isolates were
fully co-trimoxazole resistant, and this was was associated with
both folP insertion and the folA I100L substitution. The single
β-lactam-non-susceptible (NS) serotype 33F strain (phenotype
IISSR) featured a PBP proﬁle (4:23:7) suggestive of previous
horizontal transfer(s) of PBP gene sequences from a CC558
donor strain into a common 33F/CC100 strain, as 1a-4 and
2x-7 are found nearly exclusively in β-lactam-NS 35B/CC558
strains (Table 1). Although 2b-23 is unique in our database to
this speciﬁc serotype 33F isolate, it also appears to have orig-
inated from a recombination event with a β-lactam-NS strain,
as it contains six substitutions that closely neighbour the active
site serine SXXK and SXN. These include three of four sub-
stitutions in this region (T426K, Q427L, and T446A) that are
associated with intermediate penicillin resistance [15].
Serotypes 15B and 15C
Serotypes 15B and 15C show nearly identical CC distributions
(data not shown), owing to their frequent interconversionlinical Microbiology and Infectious Diseases, CMI, 22, 60.e9–60.e29
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TABLE 1. Summary of key features of year 2009, 2012 and 2013 IPD isolates: WGS-based identiﬁcation of serotype, multilocus sequence types, pilus subunit detection, penicillin-
binding protein transpeptidase proﬁles, and resistance determinants correlated with phenotypic dataa
Serotype, isolates
characterized in
years 2009:2012:2013 b
Reference
CC STc
CC percentage of
the serotype during STd (relation to
reference CC ST)e
(no. identiﬁed)
PI-1, PI-2 (no.
when variation)
PBP 1a:2b:2x
proﬁle (no.
when variation)
β-Lactam
R proﬁlef (no.
when variation)
Non-β-lactam
R proﬁleg (no.
when variation)
Resistance determinant
proﬁle h (no. characterized
as showna)2009 2012–2013
1, 7:0:1 (6:0:1) 227 85.7 100 227 (4) – , + 23:0:2 SSSSS SSSSS Negative (4)
304 (TLV) (1) – , + 23:4:2 SSSSS SSSSS Negative (1)
306 (DLV) (1) – , + 23:6:5 SSSSS SSSSS Negative (1)
2296 14.3 0 2296 (1) – , – 0:4:0 SSSSS SSSSS Negative (1)
3, 13:5:9 180 100 93.3 180 (18) – , – 2:3:2 (15)
2:0:2 (3)
SSSSS SSSSS Negative (17)
RRSRR ermB, tetM, cat (1)
10179 (SLV) (1) – , – 2:3:2 SSSSS SSSSS Negative (1)
1220 0 6.7 1220 (1) – , – 62:0:0 SSSSS SSSSS Negative (1)
4, 1:1:2 695 100 33.3 899 (SLV) (1) +, – 0:0:3 SSSSS SSSSS Negative (1)
205 (TLV) (1) +, – 0:0:3 SSSSS SSSSS Negative (1)
437 0 66.7 10173 (TLV) (1) – , – 1:0:0 SSSSS SSISS folP insertion (1)
10172 (DLV) (1) – , – 3:0:0 SSSSS SSISS folP insertion (1)
5, 2:0:0 289 100 0 Not done (2) – , – Not done SSSSS SSSSS Not done (2)
6C, 9:5:0 1092 11.1 40.0 1092 (2) +, – 6:7:8 IISSR SSRSS folA I100L + folP insertion (2)
15:7:8 RRIIH
490 (SLV) (1) +, – 1:4:2 SSSSS RSISS mef, folA I100L (1)
138 22.2 40.0 138 (2) +, – 2:0:3 SSSSS RRSSS 23S-A2061G (1)
0:0:3 SSSSS SSISS folP insertion
639 (DLV) (1) – , – 2:0:0 SSSSS RSSSS mef (1)
4343 (SLV) (1) +, – Not done SSSSS SSRSS Not done (1)
1292 22.2 0 1292 (1) – , – 19:31:8 IISSR RSRSS mef, folA I100L + folP insertion (1)
9455 (SLV) (1) – , – 19:31:8 IISSS RSRSS mef, folA I100L + folP insertion (1)
473 22.2 0 473 (1) – , – 0:4:2 SSSSS SSSSS Negative (1)
5501 (SLV) (1) – , – 1:0:21 SSSSS SSSSS Negative (1)
338 11.1 20.0 338 (1) – , – Not done ISSSS SSISS Not done (1)
2777 (SLV) (1) 2:1:1 ISSSS SSSSS Negative (1)
4343 (SLV) (1) – , – Not done SSSSS SSISS Not done (1)
395 11.1 0 395 (1) – , – 2:6:0 SSSSS SSSSS Negative (1)
7C, 0:1:1 1797 0 100 1797 (1) – , – 2:4:6 SSSSS SSSSS Negative (1)
10151 (SLV) (1) – , – 2:4:6 SSSSS SSSSS Negative (1)
7F, 71:3:2 191 97.2 80.0 191 (62) – , + 2:0:2 SSSSS SSSSS Negative (62)
9072 (SLV) (1) – , + 2:0:42 SSSSS SSSSS Negative (1)
10162 (SLV) (1) – , + 2:0:2 SSSSS SSSSS Negative (1)
220 2.8 20.0 218 (SLV) (1) – , – 2:0:2 SSSSS SSSSS Negative (1)
1176 (TLV) (2) – , – 2:0:2 SSSSS SSSSS Negative (2)
8, 3:4:2 1480 66.7 100 1480 (6) – , – 3:5:5 (5)
63:5:5 (1)
SSSSS SSSSS Negative (6)
1268 (1) – , – 3:5:5 SSSSS SSSSS Negative (1)
53 33.3 0 10155 (SLV) (1) – , – 3:6:5 SSSSS SSSSS Negative (1)
9N, 4:2:0 66 50.0 100 66 (3) – , – 1:0:0 (2)
1:70:66 (1)
SSSSS SSSSS Negative (3)
632 (SLV) (1) – , – 1:0:0 SSSSS SSSSS Negative (1)
1257 25.0 0 1257 (1) – , – 1:4:2 SSSSS SSSSS Negative (1)
4666 25.0 0 4666 (1) – , – 23:0:0 SSSSS SSSSS Negative (1)
9V, 2:0:0 156 2 (100) 0 156 (2) +, – 15:12:18 RIIIH RSRSS mef, folA I100L + folP insertion (1)
HRIRH RSRSS mef, folA I100L + folP insertion (1)
10A, 8:8:4 97 87.5 91.7 816 (DLV) (12) – , – 0:0:2 SSSSS SSSSS Negative (11)
RSSSS mef (1)
97 (4) – , – 0:0:2 (2)
0:40:2 (2)
SSSSS SSSSS Negative (4)
585 (SLV) (1) – , – 0:0:2 SSSSS SSSSS Negative (1)
3617 12.5 0 3617 (1) – , – 23:4:0 SSSSS SSIRS folP insertion, tetM (1)
3735 0 8.3 10177 (DLV) (1) – , – 2:0:0 SSSSS SSISS folP insertion (1)
Continued on next page
C
M
I
M
etcalf
et
al.
Population-based
invasive
pneum
ococcalstrain
distribution
in
the
U
SA
60.e14
C
linicalM
icrobiology
and
Infection
published
by
Elsevier
Ltd
on
behalfofEuropean
Society
ofC
linicalM
icrobiology
and
Infectious
D
iseases,CM
I,22,60.e9
–60.e29
T
his
is
an
open
access
article
under
the
C
C
BY
license
(http://creativecom
m
ons.org/licenses/by/4.0/)
TABLE 1. Continued
Serotype, isolates
characterized in
years 2009:2012:2013 b
Reference
CC STc
CC percentage of
the serotype during STd (relation to
reference CC ST)e
(no. identiﬁed)
PI-1, PI-2 (no.
when variation)
PBP 1a:2b:2x
proﬁle (no.
when variation)
β-Lactam
R proﬁlef (no.
when variation)
Non-β-lactam
R proﬁleg (no.
when variation)
Resistance determinant
proﬁle h (no. characterized
as showna)2009 2012–2013
11A, 5:6:2 62 100 100 62 (8) – , + (3)
– , – (5)
2:6:0 (5)
2:6:38 (1)
2:6:10 (2)
SSSSS SSSSS Negative (2)
RSSSS mef (2)
RSRSS mef, folA I100L + folP insertion (1)
SSISS folA I100L (1)
folP insertion (1)
SSRSS folA I100L + folP insertion (1)
10154 (SLV) (1) – , – 0:6:10 SSSSS RSRSS mef, folA I100L + folP insertion (1)
11B, 0:0:1 8954 0 1 (100) 10153 (DLV) (1) – , – 1:0:0 SSSSS RSRSS mef, folA I100L + folP insertion (1)
12F, 7:7:7 220 85.7 100 220 (8) – , – 0:0:2 (6)
0:0:17 (4)
SSSSS SSSSS Negative (8)
RSSSS mef (1)
SSISS folP insertion (1)
218 (SLV) (6) – , – 0:0:0 (5)
0:0:2 (1)
SSSSS RSSSS mef (2)
RSISS mef, folA I100L (1)
SSSSS Negative (3)
10171 (DLV) (1) – , – 0:0:0 SSSSS RSISS mef, folP insertion (1)
1176 (TLV) (1) – , – Not done SSSSS SSSSS Not done
3776 14.3 0 3776 (1) – , – 23:4:1 SSSSS SSSSS Negative (1)
13, 2:0:0 574 100 0 574 (1) +, – 11:0:0 SSSSS SSSSS Negative (1)
9462 (SLV) (1) +, – 11:0:0 SSSSS SSSSS Negative (1)
15A, 5:5:3 63 80.0 75.0 63 (4) – , – 24:27:28 (2) ISSSS RRIRS ermB, folP insertion, tetM (2)
24:27:35 (1) IISSS RRSSS ermB, tetM (1)
24:73:114 (1) IISIH RRIRS ermB, folP insertion, tetM (1)
9939 (SLV) (3) – , – 24:27:28 (1)
24:22:28 (2)
ISSS RRIRS ermB, folP insertion, tetM (3)
3058 20.0 0 Not done (1) – , – Not done SSSSS SSSSR Not done (1)
156 0 25.0 3811 (SLV) (2) +, – 1:0:0 SSSSS SSSSS Negative (2)
15B + 15C,
14:24:28 (14:24:26)
199 35.7 47.0 199 (8) – , – 2:0:2 SSSSS SSSSS Negative (8)
RSSSS mef (1)
0:0:0 SSSSS SSSSS Negative (2)
2:0:0 SSSSS SSSSS Negative (2)
RSSSS mef (1)
2:0:12 SSSSS SSSSS Negative (2)
1:0:0 SSSSS SSSSS Negative (1)
1:0:6 SSSSS SSSSS Negative (1)
5:0:2 SSSSS SSSSS Negative (1)
200 (SLV) (1) – , – 1:0:0 SSSSS SSSSS Negative (1)
10156 (DLV) (1) – , – 0:0:0 SSSSS SSSSS Negative (1)
3280 28.6 23.5 3280 (10) +, – (10)
– , – (1)
7:8:9 IISSS (9)
ISSSS (1)
IISSR (1)
RSIRS (10) mef, folP insertion, tetM (10)
RSIIS (1) mef, folP insertion (1)
10611 (SLV) (3) +, – 7:8:9 IISSS RSISS mef, folP insertion, tetM (3)
7479 (SLV) (2) +, – 7:8:9 IISSS RSISS mef, folP insertion, tetM (2)
8300 (DLV) (1) – , – 7:1:30 ISSSS SSRSS folA I100L + folP insertion (1)
1262 7.1 13.7 1262 (7) – , – 2:0:2 (6)
14:0:2 (2)
2:0:31 (1)
SSSSS SSISS (7) folP insertion (7)
SSSSS (2) Negative (2)
156 7.1 9.8 162 (SLV) (5) +, – 1:0:0 SSSSS SSSSS Negative (5)
608 (SLV) (1) +, – 2:12:2 SSSSS SSISS folA I100L (1)
346 7.1 2.0 346 (2) – , – 20:18:35 IISSS SSSSS Negative (2)
81 0 2.0 83 (SLV) (1) – , – 15:12:18 HRIIH RRRRR ermB, folA I100L + folP insertion,
tetM, cat (1)
193 14.3 0 10227 (SLV) (1) – , – 0:0:0 SSSSS RSISS mef, folA I100L (1)
8495 0 2.0 8459 (1) +, – Not done SSSSS RSRSS mef, folP insertion (1)
16F, 7:1:6 (7:1:5) 659 71.4 50.0 659 (2) – , – (1)
– , + (1)
9:0:3 SSSSS SSSSS Negative (2)
3157 (DLV) (1) – , – 0:0:3 SSSSS SSSSS Negative (1)
995 (SLV) (2) – , – 9:4:3 SSSSS SSSSS Negative (2)
10170 (SLV) (1) – , – 9:0:3 SSSSS SSSSS Negative (1)
10152 (DLV) (1) – , – 9:4:3 SSSSS RSSSS mef (1)
10224 (DLV) (1) – , – 9:4:3 SSSSS SSSSS Negative (1)
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1840 14.3 33.3 1840 – , – 0:10:2 SSSSS SSSSS Negative (1)
10148 (SLV) (2) – , – 0:10:14 SSSSS SSSSS Negative (2)
570 0 16.7 570 – , – 0:6:2 SSSSS SSSSS Negative (1)
2966 14.3 0 2966 – , – 37:4:2 SSSSS RRSRR ermB, tetM, cat (1)
17F, 4:0:3 392 75.0 100 392 – , – 11:0:0 SSSSS SSSSS Negative (3)
RSSSS mef (1)
10176 (SLV) – , – 11:0:0 SSSSS RSSSS mef (1)
338 25.0 0 338 – , – Not done ISSSS SSISS Not done (1)
18C, 0:1:0 496 0 100 496 – , – 0:0:0 SSSSS SSSSS Negative (1)
19A, 190:20:14
(189:20:14)
320 42.9 32.4 320 +, + (66) 13:11:16 (58)
13:14:16 (1)
HHRRH (46)
HHHRH (5)
HHRIH (5)
RHRIH (2)
RHRRH (1)
RRRSH (1)
RRRRS (63)
RSRRS (1)
RRRSS (2)
mef, ermB, folA I100L + folP insertion,
tetM (66)
13:14:26 (3)
13:11:33 (2)
HHRHH (5)
13:11:26 (1) RHRHH (1)
1451 (SLV) (16) +, + 13:11:16 (12)
13:14:16 (1)
HHRRH (11)
HHRIH (1)
RHRIH (1)
RRRRS mef, ermB, folA I100L + folP
insertion, tetM (15)
mef, ermB, folA I100L, tetM (1)
13:28:37 (1)
13:11:113 (1)
HHHHH (2)
271 (SLV) (2) +, + 13:14:20 HHRIH RRRRS mef, ermB, folA I100L + folP
insertion, tetM (2)
2514 (SLV) (2) +, + 13:11:16 HHRIH
HHRRH
RRRRS mef, ermB, folA I100L + folP
insertion, tetM (2)
9356 (SLV) (2) +, + 13:11:16 HHRIH
HHRRH
RRRRS mef, ermB, folA I100L + folP
insertion, tetM (2)
9630 (SLV) (1) +, + 13:11:16 HHRRH RRRRS mef, ermB, folA I00L + folP ins,
tetM (1)
10143 (SLV) (1) +, + 13:11:16 HHRHH RRRRS mef, ermB, folA I100L + folP
insertion, tetM (1)
10223 (SLV) (1) +, + 13:11:16 HHRRH RSRSS mef, folA I100L + folP
insertion (1)
10144 (SLV) (1) +, + 13:14:26 HHRHH RSRRS mef, ermB, folA I100L + folP
insertion, tetM (1)
199f 27.0 23.5 199 (27) – , – 0:29:11 (22)
33:29:11 (3)
8:29:11 (1)
32:29:11 (1)
ISSSS (21)
SSSSS (5)
IISSS (1)
SSSSS (10)!
RSRSS (8)+
RSISS (1)+
SSRSS(6)*
SSISS (1)#
RSSSS (1)@
Negative (10)!
mef, folA I100L + folP
insertion (9)+
folA I100L + folP
insertion (6)*
folP insertion (1)#
mef (1)@
18:37:8 (1) IHRIH (1)
667 (SLV) (8) – , – 0:0:0 SSSSS SSSSS Negative (8)
1756 (SLV) (2) – , – 0:29:11 ISSSS SSSSS (1)
RRSSS (1)
Negative (2)
1673 (SLV) (1) – , – 0:29:11 ISSSS SSSSS Negative (1)
2540 (SLV) (2) – , – 0:29:11 SSSSS SSSSS Negative (1)
ISSSS SSISS folP insertion (1)
2273 (DLV) (1) – , – 0:29:11 ISSSS SSRSS folA I100L + folP insertion (1)
2269 (SLV) (1) – , – 33:29:11 ISSSS RSRSS mef, folA I100L + folP insertion (1)
4262 (SLV) (1) – , – 8:29:8 ISSSI RSRSS mef, folA I100L + folP insertion (1)
2344 (SLV) (2)+ – , – 18:12:8 RIIIH RSRSS mef, folA I100L + folP insertion (1)
IISIH SSRSS folA I100L + folP insertion
695 11.1 32.4 695 (24) +, – 8:0:11 ISSSS (20)
SSSSS (4)
SSSSS (20) Negative (20)
RSSSS (4) mef (4)
2365 (TLV) (1) +, – 0:29:11 SSSSS SSSSS Negative (1)
230 3.2 5.9 230 (3) – , – 17:15:22 (2) ISSSS SSRRS folA I100L + folP insertion, tetM (3)
17:7:8 (1) RIISH
276 (SLV) (1) – , – 17:15:18 HISIH RRIRS ermB, folP insertion, tetM (1)
6741 (SLV) (1) – , – 17:15:22 ISSSS SSRRS folA I100L + folP insertion, tetM (1)
319 (SLV) (1) – , – 10:0:13 IISSS RRRRS ermB, folA I100L + folP insertion, tetM (1)
3936 (SLV) (1) – , – 17:15:22 ISSSS SSRRS folA I100L + folP insertion, tetM (1)
10160 (DLV) (1) – , – 17:15:22 ISSSS SSRRS folP insertion, tetM (1)
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TABLE 1. Continued
Serotype, isolates
characterized in
years 2009:2012:2013 b
Reference
CC STc
CC percentage of
the serotype during STd (relation to
reference CC ST)e
(no. identiﬁed)
PI-1, PI-2 (no.
when variation)
PBP 1a:2b:2x
proﬁle (no.
when variation)
β-Lactam
R proﬁlef (no.
when variation)
Non-β-lactam
R proﬁleg (no.
when variation)
Resistance determinant
proﬁle h (no. characterized
as showna)2009 2012–2013
1339 5.3 0 1339 (3) +, + (2)
– , + (1)
27:30:8 RRIIH (2)
HIISR (1)
RSRSS mef, folA I100L + folP insertion (3)
2268 (SLV) (3) +, + 27:36:8 HHRRH (2) RSRSS (2) mef, folA I100L + folP insertion (2)
HHHRH (1) RSISS (1) mef, folP insertion
2270 (SLV) (1) +, + 27:30:8 RRRIH RSRSS mef, folA I100L + folP insertion (1)
8207 (SLV) (1) +, + 27:11:8 HHRRH RSRSS mef, folA I100L + folP insertion (1)
10178 (SLV) (1) +, + 27:30:8 RHRIH RSRSS mef, folA I100L + folP insertion (1)
10159 (DLV) (1) +, + 27:30:8 HRRIH RSRSS mef, folA I100L + folP insertion (1)
156 4.2 0 156 (5) +, – 29:12:26 (4) HRIHH RSRSS mef, folA I100L + folP insertion (5)
41:12:36 (1) HHRIH
4026 (SLV) (2) +, – 28:14:36 HHRIH RSRSS mef, folA I100L + folP insertion
HHRRH RSISS mef, folP insertion
166 (SLV) (1) +, – 15:12:7 HRRRH RRRRS ermB, folA I100L + folP
insertion, tetM (1)
10225 (TLV) (1) +, – 65:38:36 HHHRH RSRSS mef, folA I100L, folP insertion (1)
338 3.2 2.9 8197 (DLV) (2) – , – 17:1:22 ISSSS SSISS folP insertion (2)
338 (1) – , – 0:1:1 ISSSS SSSSS Negative (1)
10150 (DLV) (1) – , – 17:1:22 ISSIS SSISS folP insertion (1)
558g 1.1 0 558 (2) +, – 4:7:7 (2009) IRISH RSSSS mef (1)
4:7:16 (2006) RRIIH SSSSS Negative (1)
66 0.5 0 66 (1) – , – 0:0:0 SSSSS SSSSS Negative (1)
81 0.5 0 2346 (SLV) (1) – , – 15:12:18 HRRRH RRRRR ermB, folA I100L + folP
insertion, tetM, cat (1)
138 0.5 0 639 (DLV) (1) – , – 2:0:0 SSSSS SSSSS Negative (1)
292 0.5 0 292 (1) – , – 30:0:0 SSSSS SSSSS Negative (1)
2062 0 2.9 2062 (1) – , – 16:13:19 ISSSS SSRSS folA I100L + folP insertion (1)
63 0.5 0 63 – , – Not done ISSSS RRSRS Not determined (1)
1374 1374 (1) +, – 23:75:126 SSSSS RRIRS ermB, tetM, folP insertion
19F, 3:3:2 320 33.3 40.0 271 (SLV) +, + 13:14:20 (1) HHRIH RRRRS mef, ermB, folA I100L + folP
insertion, tetM (3)13:16:47 (1) RIIIH
13:14:115 (1) HHRHH
251 0 40.0 251 (1) +, – 2:0:0 SSSSS SSSSS Negative (1)
654 (SLV) (1) +, – 2:0:0 SSSSS SSSSS Negative (1)
177 1 (33.3) 0 179 (SLV) (1) +, – 34:32:43 RISIH RRSRS ermB, tetM (1)
346 0 20.0 1203 (SLV) (1) – , – 20:18:15 SSSSS SSSSS Negative (1)
230 33.3 0 Not done (1) – , – Not done SSSSS SSSSS Not done (1)
21, 3:3:5 (3:2:5) 432 33.3 71.4 432 (6) – , – 0:0:2 SSSSS SSSSS Negative (6)
193 66.7 28.6 193 (2) – , – 2:0:2 SSSSS SSSSS Negative (2)
3689 (SLV) – , – 2:0:2 SSSSS SSSSS Negative (1)
22F, 23:21:19 433 100 97.6 433 (47) – , – 1:2:2 (42)
1:2:27 (2)
1:2:59 (3)
SSSSS SSSSS Negative (44)
RSSSS mef (3)
7314 (SLV) (3) – , – 1:2:2 SSSSS RSSSS mef (3)
9456 (SLV) (1) – , – 1:0:2 SSSSS SSSSS Negative (1)
10166 (SLV) (1) – , – 1:2:2 SSSSS SSSSS Negative (1)
10164 (SLV) (1) – , – 1:2:2 SSSSS RSSSS mef (1)
10165 (SLV) (1) – , – 1:2:2 SSSSS SSSSS Negative (1)
10167 (SLV) (1) – , – 1:2:2 SSSSS RSSSS mef (1)
10163 (DLV) (3) – , – 1:2:2 SSSSS RSSSS mef (2)
SSSSS Negative (1)
10226 (DLV) (1) – , – 1:2:2 SSSSS RSSSS mef (1)
698 0 2.4 698 (1) – , – 0:2:0 SSSSS SSSSS Negative (1)
23A, 1:4:4 338 100 75.0 338 (7) – , – 0:1:1 (5)
19:1:24 (1)
1:1:48 (1)
ISSSS (6)
IISSS (1)
SSISS (3) folA I100L (2)
folP insertion (1)
SSSSS (2) Negative (2)
RSSSS (1) mef (1)
RRRSS (1) ermB, folA I100L + folP insertion (1)
42 0 25.0 10147 (SLV) (1) – , – 2:0:6 SSSSS SSSSS Negative (1)
1839 (DLV) (1) – , – 12:0:0 SSSSS SSSSS Negative (1)
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23B, 7:7:7 (7:6:7) 338 42.9 38.5 1373 (DLV) (6) – , – 0:1:1 (5)
21:1:1 (1)
ISSSS (5)
SSSSS (1)
SSISS folP insertion (3)
SSSSS Negative (3)
4534 (TLV) (1) – , – 7:21:1 (1) ISSSS RSISS mef, folP insertion (1)
10149 (DLV) (1) – , – 7:1:1 (1) ISSSS SSRSS folA I100L + folP insertion (1)
42 42.9 46.1 439 (SLV) (6) – , – 0:0:0 (4)
0:0:11 (1)
0:24:29 (1)
0:0:119 (1)
SSSSS SSSSS Negative (6)
RSSSS mef (1)
33 (DLV) (1) – , – 12:0:2 SSSSS SSSSS Negative (1)
1847 (DLV) (1) – , – 0:0:0 SSSSS SSSSS Negative (1)
156 0 7.7 162 (SLV) (1) +, – 0:0:0 SSSSS SSSSS Negative (1)
63 14.3 0 63 (1) – , – 24:27:28 IISSS RRSRS ermB, tetM(1)
433 0 7.7 4334 (SLV) (1) – , – 0:2:0 SSSSS SSSSS Negative (1)
23F, 1:0:0 292 100 0 2520 (TLV) (1) – , – 12:68:104 ISSSS SSRRS folA I100L + folP insertion, tetM (1)
28A, 0:0:1 494 0 1 (100) 494 (1) – , – 2:2:2 SSSSS SSSSS Negative (1)
31, 0:2:1 568 0 3 (100) 568 (2) – , – 12:0:15 SSSSS SSSSS Negative (2)
33F, 25:14:27 (25:14:25) 100 92.0 100 100 (14) – , – 2:0:6 (12)
2:20:6 (1)
64:0:6 (1)
SSSSS SSISS folP insertion (6)
RSISS mef, folP insertion (6)
SSRSS folA I100L + folP insertion (1)
RSSSS mef (1)
2705 (DLV) (34) – , – 2:0:6 (34) SSSSS RSISS (30) mef, folP insertion (30)
RSRSS (4) mef, folA I100L + folP insertion (3)
mef, folP insertion (1)
SSISS (1) folP insertion (1)
9029 (SLV) (2) – , – 2:0:6 (1) SSSSS RSISS mef, folP insertion (1)
2:9:6 (1) SSSSS SSSSS Negative (1)
717 (TLV) (2) – , – 2:0:6 (1)
2:72:6 (1)
SSSSS RRSRS ermB, tetM (2)
7507 (SLV) (1) – , – 2:0:6 (1) SSSSS RSISS mef, folP insertion (1)
10145 (DLV) (1) – , – 2:0:6 (1) SSSSS SSISS folP insertion (1)
10168 (DLV) (1) – , – 4:23:7 IISSR RSISS mef, fol insertion (1)
10142 (TLV) (1) – , – 2:0:6 (1) SSSSS RSISS mef, folP insertion (1)
10169 (DLV) (1) 2:0:6 SSSSS RSRSS mef, folA I100L + folP insertion (1)
10146 (TLV) (1) – , – 2:0:6 SSSSS RSISS mef, folP insertion (1)
60 4.0 0 60 (1) – , – 2:4:2 SSSSS SSSSS Negative (1)
1012 4.0 0 1012 (1) – , – 2:0:2 SSSSS SSSSS Negative (1)
34, 1:1:5 547 100 83.3 547 (5) – , – 0:0:2 SSSSS SSSSS Negative (5)
10157 (SLV) (1) – , – 0:0:2 SSSSS SSSSS Negative (1)
1884 0 16.6 1884 (1) – , – 0:0:0 SSSSS SSSSS Negative (1)
35B, 8:13:15 (8:13:13) 558 62.5 92.3 558 (17) +, – 4:7:7 (16)
4:7:112 (1)
4:19:7 (1)
RHIIH (6)
RHRIH (5)
RRIIH (4)
RRRIH (3)
RSSSS (17) mef (17)
RSISS (1) mef, folA I100L (1)
10222 (SLV) (1) +, – 4:7:7 RRRIH RSSSS mef (1)
10175 (SLV) (1) +, – 4:14:7 RHRIR RSSSS mef (1)
473 25.0 0 3822 (SLV) (1) – , – 23:4:21 SSSSS SSSSS Negative (1)
156 12.5 3.9 10174 (SLV) (1) +, – 4:7:18 RIIIH RSRSS mef, folA I100L + folP insertion (1)
156 (1) +, – 4:12:7 RHIIH RSRSS mef, folA I100L + folP insertion (1)
452 0 3.9 10158 (SLV) (1) – , – 0:0:0 SSSSS SSSSS Negative (1)
35F, 2:1:4 498 100 100 498 (3) – , – 0:3:3 SSSSS SSSSS Negative (3)
1635 (DLV) (2) – , – 0:3:3 SSSSS SSSSS Negative (2)
38, 13:10:12(13:10:11) 393 100 100 393 (27) – , – 2:4:0 (19)
2:4:4 (4)
2:4:41 (1)
0:0:2 (1)
SSSSS (27) SSSSS Negative (26)
SSISS folP insertion (1)
1140 (DLV) (1) – , – 2:4:0 SSSSSS SSSSS Negative (1)
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serotype 15B and 15C isolates recovered during 2005–2013,
115 (62%) were serotype 15C. The ability to resolve these two
serotypes was included within our typing pipeline, owing to the
reported low cross-reactivity of functional antibodies against
serotype 15B with serotype 15C [17], which is a consideration
in the formulation of new vaccines. These two serotypes
accounted for 84 isolates for the years for which we provided
genotyping (2008–2009 and 2011–2013), and showed a high
level of genetic heterogeneity as compared with the pre-PCV7
years, when ABCs serotype 15B/15C isolates were primarily
comprised of CC199 [14]. Although CC199 was the single
most common serotype 15B/15C CC, numerous additional
CCs as a group constituted up to 65% of these two serotypes
(Fig. 2), with CC3280 being the most frequent secondary CC.
As shown in Table 1, CC3280 has markedly more resistance
features than the other common serotype 15B/C CCs (resis-
tance to macrolides and co-trimoxazole; low-level β-lactam
resistance). Several other CCs were evident at low frequencies,
including CC156. CC156, which is characteristic of the major
serotype 9V strain that ﬂourished prior to PCV7 implementa-
tion [14], featured a number of single-locus variants within
serotypes 15A, 15B/15C and 23B that, unlike their serotype 9V
counterparts, were uniformly susceptible to β-lactams and
generally susceptible to other antibiotics (Table 1).
A single highly resistant serotype 15C strain was a single-
locus variant (ST83) of ST81, which is the genotype of the
highly successful multiresistant PMEN-1 [18]. This strain
showed moderate to high resistance to all ﬁve β-lactam classes,
and was resistant to the ﬁve additional antimicrobials listed in
Table 1. This ST83 strain shared PBP proﬁle 15:12:18, which
was also found within a multiresistant serotype 19A/ST2346
strain (ST81 single-locus variant) and two serotype 9V/ST156
strains in this study (Table 1). The 15:12:18 proﬁle is also
shared among numerous pre-PCV7 IPD isolates of serotypes
9V, 19F and 23F within CC81 and CC156 in our master
pneumococcal genome database (data not shown). Prior to this
study, ST83 was associated in the global MLST database solely
with strains collected in Asian countries during 1995–2013 that
primarily included serotype 23F strains, but also included
serotype 15B and 15C strains.
Serotype 35B
Serotype 35B was primarily comprised of the serotype 35B
ST558 complex during all 5 years, which slightly increased in
frequency during 2011–2013 (Fig. 2). This strain complex is
typically associated with the presence of pilus PI-1 and elevated
MICs for penicillin and other β-lactam antibiotics (Table 1;
Figs. 4 and 5). It is interesting that, during the pre-PCV7 years,
serotype 35B strains rarely caused IPD in children, and the nowlinical Microbiology and Infectious Diseases, CMI, 22, 60.e9–60.e29
.0/)
CMI Metcalf et al. Population-based invasive pneumococcal strain distribution in the USA 60.e20uncommon β-lactam-sensitive serotype 35B complex (CC452,
one isolate depicted in Table 1) accounted for approximately
31% of 35B IPD isolates from patients of all ages [19]. Two
additional interesting CCs were observed within serotype 35B.
A single-locus serotype 35B variant of ST473 (ST3822; also
described in Table 1) was recovered during 2009. CC473 has
been previously associated with serotypes 6A and 6C [10], and
ST3822 has been recorded from a single serotype 6A blood
isolate recovered during 2008 in Ireland (http://pubmlst.org/
spneumoniae/). Because of PBP allele and MLST associations,
the two serotype 35B/CC156 isolates (Table 1) appear to be
progeny of serotype switch events, and are described in more
detail in the section below pertaining to capsular locus
switching.
Serotype 6C
The most genetically heterogeneous NVT serotypes were se-
rotypes 6C and 15B/15C (already described). Although it
caused a low level of IPD in children aged <5 years (ﬁve to nine
isolates during each of the years 2008–2009 and 2011–2012),
serotype 6C was composed of two different CCs, four of which
were represented by single isolates (Fig. 2; Table 1). The
absence of recovered serotype 6C IPD isolates during 2013
possibly reﬂects the previously predicted PCV13 cross-
protection against serotype 6C [13].
We have veriﬁed that all of the depicted CCs shown for
serotype 6C (Fig 2), except for CC3813, have been previously
associated with serotypes 6A and 6B, including CC473 found in
the single serotype 6A isolate and CC1092 from the single
serotype 6B isolate recovered during the 5 years of the study
(both recovered during 2008) [7,10]. No serotype 6A-mediated
or serotype 6B-mediated IPD was observed during 2009–2013
in children aged <5 years, presumably because of the protection
of PCV7 (during 2009) and PCV13 (during 2012–2013).
Serotype switching events targeting the cps-internal wciN genes
that distinguish serotypes 6A and 6C appear to have occurred
many times between the different serogroup 6 lineages [7].
Serotype 15A
Most of these isolates were within CC63, which is character-
istic of the global PMEN clone PMEN-23 (http://www.
pneumogen.net/pmen/). This CC gradually became predomi-
nant within ABCs serotype 15A during 2001–2007 [10]. CC63
strains contained highly related PBP patterns that were gener-
ally associated with intermediate resistance to penicillin and
amoxycillin, with the exception of the single 24:73:114 pattern,
which was associated with intermediate resistance to cefotax-
ime and ceftriaxone, and high-level resistance to cefuroxime.
CC63 isolates were nearly uniformly resistant to erythromycin,
clindamycin, and tetracycline (ermB and tetM positive), with folAClinical Microbiology and Infection published by Elsevier Ltd on behalf of E
This is an oand/or folP mutations conferring co-trimoxazole non-suscepti-
bility (Table 1).
Two ST3811 (ST156 single-locus variant) type 15A isolates
were recovered in the post-PCV13 period, presumably
reﬂecting a past serotype switching event between a serotype
15A donor and a CC156 recipient strain. Both isolates were
sensitive to antibiotics and featured the PBP 1:0:0 proﬁle, which
is associated with basal β-lactam sensitivity (see serotypes 4, 9N
and 11B and 15B/C for additional examples of this widely
shared proﬁle in Table 1). All of the various CC156 clones
described in this study (Table 1) retain pilus PI-1 positivity that
is characteristic of the presumed serotype 9V/ST156 ancestral
strain. The major serotype 9V complex CC156, which was
predominant in the pre-PCV7 years [14], was associated with
six additional serotypes besides serotype 9V in this study
(Table 1), including 15A, 15B, 15C, 19A, 23B, and 35B.
Of the CC156 non-9V strains, only the serotype 19A and
35B variants expressed levels of β-lactam resistance similar to
that of serotype 9V/ST156. The serotype 19A/ST156 and
serotype 19A/ST166 strains each share 2b-12, which is also
found in the 9V/ST156 strain, with the 19A/ST166 strain
additionally carrying the CC156-associated 1a-15.
Serotypes 23A and 23B
It is interesting that these two serotypes are completely (23A)
or primarily (23B) associated with the two same CCs (CC338
and CC42). Although they feature different predominant STs
within CC338, strains of both serotypes within CC338 show
similar antimicrobial resistance features (Table 1).
Serotype 23B variants of CCs that are thought to have
originated within other serotypes were additionally recovered
(one or two isolates each of CC156 (9V), CC63 (15A), and
CC433 (22F)).
Serotype 17F
Serotype 17F isolates were associated with CC392 genotypes
as in the pre-PCV7 years, with the exception that a single
ST338 isolate, which was intermediately penicillin resistant and
a presumed serotype switch variant, was observed. ST338 is a
primary genotype of US serotype 23A strains, is a minor
serotype 19A genotype (Table 1), and has been reported in the
past as a major serotype 23F clone [20].
NT IPD isolates
As was recently reported, isolates apparently lacking a capsule
were rare among strains causing IPD [21], consistent with the
capsule being required for establishing most invasive infections.
Of the nine NT isolates recovered over the entire 5-year
period, seven were of clonal clusters and cps locus signatures
typical of commonly occurring serotypes, including 19A/uropean Society of Clinical Microbiology and Infectious Diseases, CMI, 22, 60.e9–60.e29
pen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
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8/CC1480. Although the cps loci of these nine isolates were not
examined in detail for this study, our recent population-based
ﬁndings with NT IPD isolates from patients of all ages recov-
ered during 2006–2009 indicated that 90% of such isolates
contained cps loci, with serotype-speciﬁc cps locus signatures
and MLST types being highly associated with known serotypes
[21]. Within the 801 isolates representing 2009, 2012, and
2013, there were only four NT isolates (Table 1). The study
isolates from the 5 years included two NT ST448 isolates
(recovered during 2008 and 2012) that are of a distinct pneu-
mococcal lineage highly associated with carriage and conjunc-
tivitis. This lineage lacks capsular biosynthetic genes, and has
evolved with divergent virulence and adhesion factors [22].
Clonal distributions of PCV13 serotypes
Subset PCV7. PCV7 serotypes showed high genetic diversity,
considering their very small numbers throughout the time
period (Table 1; Fig. 2).
For 2009, 2012, and 2013, PCV7-targeted serotypes
accounted for a total of 16 isolates of serotypes 4, 9V, 18C,
19F, and 23F. Serotype 19F accounted for half of these isolates
within ﬁve different CCs that each accounted for one to three
isolates (Table 1).
Serotype 19A. The frequency of serotype 19A IPD decreased by
approximately 90% in 2012 and 2013 relative to 2009 (Fig. 1),
with all year 2009 CCs being either greatly decreased in inci-
dence or not found (Fig. 2). It is noticeable, however, that the
PCV7 escape variant 19A ST695 complex that was originally
discovered among early post-PCV7 IPD isolates [5,6] and that
spread throughout the US during subsequent years [8,23]
showed a disproportionally higher residual IPD incidence in
2013 than the other serotype 19A complexes (Fig. 2). Three
rare variants were observed within serotype 19A within
CC138, CC2062, and CC558. To our knowledge, serotype
19A/CC138 strains have not been previously described, as this
complex has been largely restricted to serotype 6B [14].
Serotype 19A/CC2062 represents numerous isolates recov-
ered recently in South Africa (see http://pubmlst.org/
spneumoniae/). Isolates within CC138 and CC2062 were not
detected in a comprehensive analysis of year 2005–2007 ABCs
serotype 19A isolates [8,24]; however, a single serotype 19A/
ST558 isolate was recovered during 2006 [8]. The two sero-
type 19A/558 variants described here (from 2006 and 2009)
appear to indicate capsular locus switching from serotype 35B
to serotype 19A, and are described in more detail below.
Serotype 7F. The second most abundant IPD serotype during
2008–2009, serotype 7F, was composed almost exclusively of
highly uniform (PI-2 positive, antimicrobial susceptible) ST191Clinical Microbiology and Infection published by Elsevier Ltd on behalf of European Society of C
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4isolates (Fig. 2; Table 1), and its incidence declined to nearly
non-detectable levels during 2013 (only two isolates
recovered).
Other PCV13 serotypes
The serotype 3/ST180 complex was associated with a small
number of cases throughout 2008–2009 and 2012–2013
(5–14 isolates each year). A single ST1220 isolate was recov-
ered during 2012.
The relatively rare IPD serotypes 1 and 5 each mainly rep-
resented single CCs, although, as shown in Table 1, there was
considerable MLST variability within a small sample of the PI-2
positive CC227. The single outlier genotype ST2296 was from
the single serotype 1 isolate recovered during 2013. There were
no serotype 1 isolates recovered during 2011–2012.
Identiﬁcation of donor, recipient and progeny strains in
serotype switch events by the use of MLST and PBP
data
The two serotype 19A/CC695 variants 19A/ST695 and 19A/
ST2365 were initially discovered and described as vaccine
escape variants in the post-PCV7 years [5,24], and were both
later characterized at the genomic sequence level [6,23].
Genomic analysis of several independent isolates of these var-
iants was performed. In addition, several independent isolates
of the deduced serotype 19A/CC199 donor strains and sero-
type 4/ST695 recipient (recipient 1 in Fig. 3A) [6] were also
identiﬁed, although a serotype 4 recipient strain corresponding
to serotype 19A/ST645 donor strain 2 and serotype 19A/
ST2365 progeny strain 2 was not found among ABCs surveil-
lance isolates. Genomic comparisons of multiple isolates of the
donor, recipient and progeny strains depicted in Fig. 3A
revealed that each of the two progeny strains arose through an
independent multifragment recombination event from serotype
19A/CC199 donor strains [6,23]. The published pbp1a and
pbp2x sequences from the putative serotype 19A/ST199 donor
and serotype 4/ST695 recipients in the previous study [6] were
identical within their overlaps with the entire 1a-8 and 2x-11
sequences found in all 22 19A/ST695 isolates recovered during
2009, 2012, and 2013, and also in a single serotype 19A/ST199
isolate (8:29:11) recovered during this period (Table 1). The
8:29:11 PBP proﬁle is also represented in multiple serotype
19A/ST199 isolates in our pre-PCV7 ABCs genomic database
(not shown). The sensitive PBP pattern 0:0:0 was predominant
(14 of 20 isolates) among serotype 4/ST695 isolates in our
database from 1998 to 1999 (whereas serotype 4/ST695 IPD
isolates were common during this time, serotype 19A/ST695
isolates were not found [10,25]). Thus, it is likely that 2x-11,
cps19A and 1a-8 were transferred and integrated into a sero-
type 4/ST695 recipient to concurrently facilitate a serotype 4 tolinical Microbiology and Infectious Diseases, CMI, 22, 60.e9–60.e29
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FIG. 3. (a). Diagrammatic representations of independent and potentially PCV7 vaccination driven serotype switch involving PCV13 serotype donors
(19A) and PCV7 serotype (4) recipient. (b) Two independent potential vaccine-escape events with non-vaccine serotype donor (35B) and PCV7 serotype
recipient (9V). (c). Two independent serotype switch events involving non-vaccine type (35B) recipient and PCV13 type donor(s). Putative donor,
recipient and progeny strains were deduced from multilocus sequence type and penicillin-binding protein proﬁles. Markers in the progeny that are shared
with the donor share the same colour font, which differs from that in the recipient. CC, clonal complex; ST, sequence type.
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60.e23 Clinical Microbiology and Infection, Volume 22 Number 1, January 2016 CMIserotype 19A switch and reduced β-lactam susceptibility
(penicillin MICs of 0.06–0.12 mg/L) [6]. We observed that the
1a-0 and 2x-0 sequences from the serotype 4/ST695 isolates
are identical to the sensitive TIGR4 strain, and that the donor
and progeny 1 1a-8 and 2x-11 contain mosaic sequences with
substitutions previously associated with β-lactam resistance
[26,27].
In the previous study [6], another serotype 19A/CC199
(ST645, a single-locus variant of ST199) strain was identiﬁed as
the likely donor in a second independent serotype 4 to sero-
type 19A switch. Although a CC695 recipient strain was not
identiﬁed, the preponderance of serotype 19A/CC199 isolates
with a 0:29:11 PBP proﬁle (Table 1) and the observation of this
same proﬁle in serotype 19A/ST2365 (progeny 2) are indicative
of co-replacement of the cps4 and ﬂanking 2x marker of a
recipient CC695 strain with the donor cps19A and 2x-11. This
is also consistent with the single observed unlinked recombi-
nation event whereby the closely linked CC695 ddl18 (exclu-
sively found within serotype 4/CC695 strains in our database)
and 2b-0 chromosomal segment was replaced by the corre-
sponding DNA fragment from serotype 19A/CC199 containing
ddl14 and 2b-29 (Fig. 3A) [23]. We believe that the serotype
19A/ST2365 progeny 2 strain has reduced penicillin suscepti-
bility (we have observed these strains to have MICs of
0.06–0.12 mg/L) owing to the 2x-0 to 2x-11 replacement event.
The putative unlinked replacement of 2b-0 with 2b-29 is not
expected to contribute to β-lactam resistance, given the lack of
key substitutions within 2b-29 associated with resistance [15],
even though these two pbp2b transpeptidase regions vary in six
of 278 residues. The progeny 2 variant 19A/ST2365 shares the
complete 0:29:11 proﬁle with the serotype 19A/CC199 donor
(Fig. 3A). These two different recombination events represent
two of the previously depicted nine fragments within serotype
19A/ST2365 progeny strains that did not match known sero-
type 4/CC695 recipient genomes and matched a common
serotype 19A/CC199 putative donor strain [23].
Another likely example (Fig. 3B) of pneumococcal conjugate
vaccine escape capsular switching is shown by two putative
independent switch events involving serotype 35B/ST558 and
serotype 9V/ST156 as donor and recipient, respectively. The
serotype 35B/ST156 (progeny 1 strain in Fig. 3B) retained all
seven ST156 MLST alleles and the 2b-12 characteristic of this
complex; however, 1a-4 and 2x-7 were apparently co-
integrated with cps35B into this progeny 1 strain during the
double-crossover serotype replacement event. In the progeny 2
strain (serotype 35B/ST10174), it appears that the region
encompassing cps9V and its ﬂanking 1a-15 was replaced by
cps35B and its ﬂanking 1a-4, whereas 2x-18 ﬂanking the
opposite end of cps9V was unaffected during this replacement
event. As in the unlinked replacement event described in theClinical Microbiology and Infection published by Elsevier Ltd on behalf of European Society of C
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4Fig. 3A progeny 2 strain, a second, unlinked, double-crossover
event seems likely to have occurred within this progeny strain,
resulting in replacement of the CC156 ddl-1 and neighbouring
2b-12 with pbp2b-7 and ddl-97. Besides this serotype 35B/
ST10174 variant, the ddl-97 allele has been exclusively associ-
ated with ABCs 35B/CC558 strains during the past 20 years
(data not shown).
A third example of a likely serotype switch strain set (donor,
recipient, two progeny strains) is shown in Fig. 3C (serotype
35B to serotype 19A). Both serotype 19A/ST558 isolates are
depicted in Table 1 and in Fig. 3C. Each isolate has two or three
of the PBP alleles within pattern 4:7:7, and susceptibility proﬁles
that are found in most common serotype 35B/ST558 isolates
(Table 1). As in the case with the putative serotype 9V to
serotype 35B replacement event depicted in Fig. 3A, the
differing PBP proﬁles of the progeny strains are suggestive of
two independent serotype switch events: one involving co-
replacement of cps35B and 2x-7 with cps19A and 2x-16 (prog-
eny 1, recovered during 2006), and the other solely involving
replacement of cps35B with cps19A (progeny 2, recovered
during 2009). Although the predominance of 2x-16 within the
serotype 19A/CC320 strain (Fig. 1) that was highly prevalent
during the pre-PCV13 period is strongly suggestive of its role as
a donor strain in this switch event, the PBP pattern data of the
progeny 2 serotype 19A strain does not provide evidence of
the 19A donor strain genotype.
Removal of strains positive for pilus determinants and
resistance genes by continued vaccination
Concurrently with the dramatic decrease in the incidence of
IPD that occurred in the period 2011–2013, there were de-
creases in the incidence rates of strains genetically positive for
all three categories of pilus determinants, including PI-1-positive
strains, PI-2-positive strains, and strains positive for both PI-1
and PI-2 (Fig. 4). The incidence of strains positive for only PI-
1 decreased by 32–55% in 2008–2009 relative to
2011–2013, primarily because of the removal of the serotype
19A/ST695 and serotype 19A/ST156 strains. A small increase in
the incidence of the PI-1 positive NVT serotype 35B complex
was observed. The incidence of strains positive for PI-2
decreased even more dramatically post-PCV13, owing to the
decrease in the incidence of the serotype 7F/ST191 complex.
Serotype 19A/ST320 accounted for almost all of the isolates
that were positive for both PI-1 and PI-2 throughout all years,
and was the sole positive strain detected during 2013 after a
decrease of approximately 97% relative to 2009. The residual
strains positive for both PI-1 and PI-2 during 2011–2012 were
also of PCV13 serotypes, including serotype 19A/ST1339 and
the rarely occurring PCV7 serotype 19F strains that are highly
related to 19A/ST320 (see Table 1 for strain features).linical Microbiology and Infectious Diseases, CMI, 22, 60.e9–60.e29
.0/)
FIG. 4. Decreases in the incidence rates of invasive pneumococcal disease (IPD) isolates positive for pilus determinants associated with decreases in
pneumococcal clonal complexes after 13-valent pneumococcal conjugate vaccine (PCV13) implementation (2011–2013) in early 2010 (arrows). Bars
1–5 and 6–10 from the left indicate isolates positive for only PI-1 and PI-2, respectively. Bars 11–15 indicate isolates positive for both PI-1 and PI-2. A
horizontal line on each bar indicates the cut-off between PCV13 serotype plus 6C strains (below the line) and non-PCV13 serotype strains (above the
line). PCV7, seven-valent pneumococcal conjugate vaccine.
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resistance throughout the period 2008–2009 was serotype
19A/CC320 (Fig. 5). Resistance during this period became
more common among pneumococci, because of a combination
of additional serotype 19A CCs and several other residual
PCV7 CCs. The major contributor to the penicillin resistance
phenotype (with and without erythromycin resistance) during
2012–2103 was serotype 35B/CC558, which showed a mod-
erate increase relative to previous years. Serotype 33F/CC100
became the predominant erythromycin-resistant/clindamycin-
sensitive IPD strain complex during 2013. The incidence of
isolates that were erythromycin resistant (owing to mef and/or
ermB determinants) decreased by 56–60% during 2012–2013
relative to 2009, whereas the clindamycin resistance conferred
by ermB decreased by 81–87% (ermB co-confers erythromycin
resistance in almost all strains). Other resistance phenotypes
showed similar dynamics, with serotype 19A/CC320 and other
PCV13 CCs declining, leaving non-PCV13-targeted serotypes as
the residual contributors to resistance. The last six combina-
tions of resistance depicted in Fig. 5 were largely eliminated
through removal of serotype 19A/CC320, with no indicationsClinical Microbiology and Infection published by Elsevier Ltd on behalf of E
This is an oof new emergent complexes. The only strains that were
resistant to all six antimicrobials depicted in Fig. 5 (penicillin,
cefotaxime and/or ceftriaxone, erythromycin, clindamycin, co-
trimoxazole and tetracycline) during 2008–2013 were sero-
type 19A/CC320 (many isolates) serotype 19A/CC81 (four
recovered during 2008–2009), serotype 19F/CC320 (one
recovered during 2012), and serotype 15C/CC81 (one recov-
ered during 2013). Representatives of these strain sets are
described in Table 1.
Resistance determinants
Among the 1428 isolates from the 5 years of the study, there
was no observed resistance to ﬂuoroquinolones, rifampin,
linezolid, telithromycin, quinupristin–dalfopristin, or vanco-
mycin. Of these 1428 isolates, 724 were subjected to WGS
analysis and our automated algorithm for detecting speciﬁc
resistance determinants. Only two of the 104 instances of
combined resistance to erythromycin and clindamycin were
not attributable to ermB (Table 1). In one (serotype 6C/
ST138), the A2061G substitution, which is known to confer
resistance to macrolides and lincosamides (Table S2), wasuropean Society of Clinical Microbiology and Infectious Diseases, CMI, 22, 60.e9–60.e29
pen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
FIG. 5. Decreases in antimicrobial resistance to six different antimicrobials and their combinations associated with decreases in the incidence rates of
pneumococcal clonal complexes after 13-valent pneumococcal conjugate vaccine (PCV13) implementation in 2010. The horizontal line on each bar
indicates the cut-off between PCV13 serotype plus 6C strains (below the line) and non-PCV13 serotype strains (above the line). Note that inter-
mediate resistance is not included. co-trimoxazole; ery, erythromycin; pen, penicillin; tet, tetracycline; cli, clindamycin; cft, cefotaxime.
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(serotype 19A/ST1756). In one isolate (serotype 19A/ST320),
ermB was detected; however, the isolate was clindamycin
sensitive (Table 1). The erythromycin-resistant/clindamycin-
susceptible and chloramphenicol-resistant phenotypes in
these isolates were entirely accounted for by the mef (166
instances) and cat (four instances; see serotypes 3/CC180,
15BC/CC81, 19A/CC81, and 16F/CC2966) determinants,
respectively (Table 1). Tetracycline resistance was associated
with tetM in all instances; however, three of the 134 tetM-
positive isolates were tetracycline sensitive (two serotype 19A/
ST320 and one serotype 15A/ST63). Intermediate to full co-
trimoxazole resistance was always attributable to mutations
within one or both of folA and folP. Most instances (107/112) of
intermediate resistance were due to insertions within a hot-
spot of folP, with the other ﬁve instances being attributed to
the well-known folA I100L substitution (Table S2). Full co-
trimoxazole resistance was attributed to two unlinked muta-
tions (folP insertion and folA I100L) in 159 of 160 instances
(Table 1). In one resistant isolate, only a folP insertion was
observed (serotype 19A/ST10160).
Predicting β-lactam MICs from PBP patterns
The utility of composite PBP transpeptidase domain proﬁles as
an additional genetic and phenotypic marker in tracking
recombination events is apparent (see above). These proﬁles
are also useful for rapidly assessing MICs for different β-lactam
antibiotics. For example, 83 isolates in Table 1 that represented
seven different CCs shared proﬁle 2:0:2 and were basally
β-lactam sensitive. There were numerous additional instances
of basally sensitive proﬁles, several of which were very com-
mon. There was no instance of a basally sensitive proﬁle being
seen among strains showing resistance or reduced susceptibility
to β-lactams. As expected, most PBP proﬁles associated with
β-lactam resistance were highly associated with speciﬁc CCs.
The association of eight basally sensitive CC156 variants (pre-
sumably descendants of the highly resistant serotype 9V/ST156
strain) with two common sensitive proﬁles (0:0:0 and 1:0:0) is
consistent with the notion that clonally associated genetic de-
terminants other than PBP transpeptidase-encoding sequences
may not commonly play dominant roles in β-lactam resistance
phenotypes. Also consistent with the dominant role of PBP
transpeptidase regions in conferring β-lactam resistance is the
observation that PBP pattern 15:12:18 was solely found among
β-lactam-resistant strains of both CC156 and CC81 (serotype
9V/ST156, serotype 19A/ST2346, and serotype 15B/ST83) that
shared closely similar β-lactam MICs (data not shown). Within
given PBP patterns, there was little deviation evident in the
β-lactam resistance proﬁles for the ﬁve different classes of
antibiotics shown. When proﬁles SSSSS and ISSSS were sharedClinical Microbiology and Infection published by Elsevier Ltd on behalf of E
This is an owithin isolates sharing a PBP proﬁle (e.g. 0:29:11, shared by
many serotype 19A/CC199 isolates), the penicillin MICs for
susceptible and intermediate isolates were always 0.06 mg/L
and 0.12 mg/L, respectively. Similar observations of a one
dilution difference were generally observed throughout there
data when both intermediate and resistant, or both resistant
and highly resistant, MIC results for the different β-lactams
were observed for isolates sharing the same PBP transpeptidase
proﬁles (data not shown).DiscussionThe most important strain characteristics tracked by IPD strain
surveillance have not changed in decades. At present, the most
critical features required for vaccine evaluation and planning
and treatment recommendations are still the capsular serotypes
and antimicrobial susceptibilities. Nonetheless, population-
based assessment of invasive pneumococcal strain features at
a deeper level within individual serotypes can potentially detect
undesirable developments within this very adaptable species
that could undermine prevention efforts. For example, although
this work provides reassuring evidence that the various lineages
of the genetically complex serotype 19A appear to have either
disappeared or to cause only a small residual level of IPD, it is
conceivable that an antigenic variant of serotype 19A could
escape being targeted by PCV13. It would be logical that such a
variant would be initially detectable as a minor genetic lineage
within the serotype that shows an IPD incidence that is
inconsistently elevated as compared with other lineages of the
same serotype. Serotype 6C is an example of a serotype 6A
immunological variant that escaped notice for decades, owing
to its serological similarity to serotype 6A [28]. The detection
of serotype 6C with monoclonal antibody-based methodology
[28] allowed the use of simple PCR-based methods [7] to easily
discern serotype 6C from serotype 6A, and to allow serotype
6C inclusion for retrospective and prospective surveillance.
This serotype was almost never detected in children prior to
PCV7 implementation; however, it became readily detectable,
although not common, in paediatric IPD patients after PCV7
implementation. Serotype 6C also became a commonly carried
serotype in children [29], and has become a common cause of
IPD in adults [2]. The lack of serotype 6C IPD isolates recov-
ered in this study during 2013 from the paediatric population
gives hope that a protective effect might eventually be seen in
adults.
The invasive serotype 35B is presently composed primarily
of one CC that is potentially poised to take advantage of re-
ductions in the frequencies of other strains in the carriage
reservoir that are occurring in the post-PCV13 era. In someuropean Society of Clinical Microbiology and Infectious Diseases, CMI, 22, 60.e9–60.e29
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immediately prior to PCV7 implementation. Like the most
frequent serotype 19A IPD-causing CC during 1999 (CC199),
the major serotype 35B/CC558 strain set caused a moderate
level of IPD during the pre-PCV13 period, was β-lactam NS,
and has shown indications of increased carriage during recent
years [29]. It is now conceivable that, as the major β-lactam NS
CC in the nasopharyngeal reservoir, and with the removal of
most PCV7 and PCV13 serotype competitors, serotype 35B/
CC558 and perhaps other variants, such as serotype 35B/
CC156, will thrive. Although the serotype 35B/CC156 variant
is very rare, we did not detect serotype 19A/CC320 strains,
despite extensive genotypic surveillance of paediatric ABCs
isolates during 1999 and 2001 [14,25]; yet this complex became
the single most common cause of IPD among people of all ages
during the mid-2000s to late 2000s [8]. It is with some concern
that two independent invasive serotype 35B/CC156 isolates
(ST156 and its single-locus variant ST9910) have already been
recovered during ongoing year 2015 IPD strain surveillance
(data not shown). The serotype 19A/CC695 complex, which
originated after PCV7 implementation from independent
serotype 4 to serotype 19A switch events [5,6,8,23,24], also
emerged signiﬁcantly in a very short period after PCV7 imple-
mentation [8]. The two serotype 35B/CC156 strains described
in this study are likely to be independent immune escape var-
iants (serotype 9V to serotype 35B) that occurred after PCV7
implementation. In contrast, the two putative instances of
serotype switch that involved replacement of the NVT cps35B
locus with the PCV13 type cps19A locus (Fig. 3C) are consistent
with naturally occurring intraspecies transfers of capsular
biosynthetic and PBP genes, which were shown to be wide-
spread between commonly occurring strains before conjugate
vaccine implementation [30].
It is interesting that four of the current non-vaccine sero-
types appeared to concurrently undergo a clonal shift during
the years between the implementation of PCV7 and the
implementation of PCV13 [10]. Each of serotypes 15A, 35B,
23A and 6C were primarily associated with penicillin-
susceptible IPD isolates during 1999–2001. Within each of
serotypes 15A, 35B, and 23A, single penicillin-NS CCs (se-
rotypes 15A/CC63, CC35B/CC558, and 23A/CC338) gradu-
ally became predominant during subsequent post-
PCV13 years [10]. Serotypes 15B and 15C showed increased
antimicrobial resistance and genetic complexity as compared
with the pre-conjugate vaccine era, and is potentially poised to
signiﬁcantly emerge in the post-PCV13 era. It remains to be
determined whether post-PCV13 clonal shifts will occur
within the two predominant non-vaccine serotypes, 22F and
33F, that are each primarily represented by single β-lactam-
susceptible CCs.Clinical Microbiology and Infection published by Elsevier Ltd on behalf of European Society of C
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4The primary purpose of this work was to provide a thorough
descriptive reference for important features of IPD strains
afﬂicting our paediatric population. The secondary aim was to
implement a more informative and efﬁcient method for the
routine determination of serotypes, resistance features, pilus
determinants, and genotypes. WGS-based serotype deduction
was successful because there is remarkable sequence conserva-
tion within the cps loci for individual serotypes. An example of this
conservation is given by the wcwD7F locus used for distinguishing
serotype 7F from serotype 7A, where inactivating mutations
distinguish the rarely occurring serotype 7A from serotype 7F. Of
the 75Quellung-typed serotype 7F isolates examined, 74 shared a
perfectly conserved 9630bp wcwD7F, and one contained a single
missense (A25V) base substitution. We feel that harnessing our
ﬁrst version of an automated WGS pipeline allows us to monitor
the changes within IPD strains that are primarily driven by hori-
zontal genetic transfer events at a much deeper and detailed level.
For example, although serotype switch events can readily be
identiﬁed within isolate sets through performing multilocus
sequence typing and serotyping, the examination of switch vari-
ants in more detail will allow better elucidation of donor lineages,
and identiﬁcation and tracking of unlinked determinants that are
often simultaneously co-transferred during these events.
Genomic analyses of pneumococcal strains indicate that the term
‘serotype switch’ is an oversimpliﬁcation, and that it often involves
simultaneous recombination events at multiple unlinked chro-
mosomal loci [4,18,23].
Removing the primary IPD-causing serotypes concurrently
removed from the pneumococcal population strain reservoirs
for resistance and adhesion that are likely to serve as advan-
tages in carriage. It follows that additional advantageous features
within the species are removed or depleted from the carriage
reservoir through this strategy. It is hoped that the durability of
the protection afforded by PCV13 will approximate that of
PCV7, which, as compared with the pre-vaccination years,
reduced the incidence of paediatric IPD throughout the 2000s
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